# Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

> **NCT04087889** · — · NO_LONGER_AVAILABLE · sponsor: **Hope Biosciences LLC**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** HB-adMSCs

## Key facts

- **NCT ID:** NCT04087889
- **Lead sponsor:** Hope Biosciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04087889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04087889, "Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04087889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*